Results 111 to 120 of about 3,899,518 (170)
Some of the next articles are maybe not open access.
2020
In 1891, Dr. William B. Coley, an American surgeon, made a compelling observation that immune system can be triggered to shrink tumors. The quest to exploit the power of immunotherapy however was forestalled by an era of chemotherapy that ensued.
Ranjit, Nair, Jason, Westin
openaire +3 more sources
In 1891, Dr. William B. Coley, an American surgeon, made a compelling observation that immune system can be triggered to shrink tumors. The quest to exploit the power of immunotherapy however was forestalled by an era of chemotherapy that ensued.
Ranjit, Nair, Jason, Westin
openaire +3 more sources
T-cell therapies for T-cell lymphoma
Cytotherapy, 2019T-cell lymphomas represent a subpopulation of non-Hodgkin lymphomas with poor outcomes when treated with conventional chemotherapy. A variety of novel agents have been introduced as new treatment strategies either as first-line treatment or in conjunction with chemotherapy. Immunotherapy has been demonstrated to be a promising area for new therapeutics,
Keri Toner +2 more
openaire +2 more sources
T Cell Receptors and T Cell Development
1996Birds provide a valuable model system for the study of early development. Studies of immune system development and function in chickens have contributed to some of the central tenets in immunology. These include:(1) allorecognition by lymphocytes in graft-vs-host (GVH) reactions (Simonsen 1985), (2) clonal reactivity of immunocompetent lymphocytes ...
C H, Chen +6 more
openaire +2 more sources
The Journal of Immunology, 1972
Abstract The antigen-induced DNA synthetic response of a number of different thymocyte populations was studied in the spleens of lethally irradiated recipients by incorporation of 125I 5-iodo-2-deoxyuridine. The response of certain cell combinations was not only less than the sum of the two responding alone but less than one of the ...
Gershon, R K +3 more
openaire +2 more sources
Abstract The antigen-induced DNA synthetic response of a number of different thymocyte populations was studied in the spleens of lethally irradiated recipients by incorporation of 125I 5-iodo-2-deoxyuridine. The response of certain cell combinations was not only less than the sum of the two responding alone but less than one of the ...
Gershon, R K +3 more
openaire +2 more sources
T-Cell Receptor–Transduced T Cells
The Cancer Journal, 2015The large number of T-cell epitopes that have been found to be processed and presented on human tumors, now numbering in the hundreds, provides a rich source of targets for therapeutic interventions aimed at inducing durable tumor regression. Vaccination strategies aimed at inducing responses to these antigens have been largely ineffective, and it has ...
openaire +2 more sources
The American Journal of Medicine, 1988
Over the past few decades, a solid body of evidence has been built up linking certain autoimmune diseases to the presence of specific major histocompatibility complex haplotypes. Major histocompatibility complex products are used by the immune system to distinguish non-self from self and are important in the recognition of foreign antigen by T cells. T
N, Caccia, T W, Mak
openaire +2 more sources
Over the past few decades, a solid body of evidence has been built up linking certain autoimmune diseases to the presence of specific major histocompatibility complex haplotypes. Major histocompatibility complex products are used by the immune system to distinguish non-self from self and are important in the recognition of foreign antigen by T cells. T
N, Caccia, T W, Mak
openaire +2 more sources
New England Journal of Medicine, 2011
The pursuit of tumor-reactive T cells as a cancer therapy has continued unabated since the discovery of the graft-versus-leukemia effect in patients undergoing allogeneic hematopoietic stem-cell transplantation.1 Some successes have been noted: the adoptive transfer of Epstein–Barr virus (EBV)–specific T cells can prevent and treat post-transplantation
Walter J, Urba, Dan L, Longo
openaire +2 more sources
The pursuit of tumor-reactive T cells as a cancer therapy has continued unabated since the discovery of the graft-versus-leukemia effect in patients undergoing allogeneic hematopoietic stem-cell transplantation.1 Some successes have been noted: the adoptive transfer of Epstein–Barr virus (EBV)–specific T cells can prevent and treat post-transplantation
Walter J, Urba, Dan L, Longo
openaire +2 more sources
Annual Review of Immunology, 1998
▪ Abstract Immunological memory can be defined as the faster and stronger response of an animal that follows reexposure to the same antigen. By this definition, it is an operational property of the whole animal or the immune system. Memory cells express a different pattern of cell surface markers, and they respond in several ways that are functionally
R W, Dutton, L M, Bradley, S L, Swain
openaire +2 more sources
▪ Abstract Immunological memory can be defined as the faster and stronger response of an animal that follows reexposure to the same antigen. By this definition, it is an operational property of the whole animal or the immune system. Memory cells express a different pattern of cell surface markers, and they respond in several ways that are functionally
R W, Dutton, L M, Bradley, S L, Swain
openaire +2 more sources
Neurosurgery Clinics of North America, 2021
Chimeric antigen receptor T (CAR-T) cells, an immunotherapy that demonstrates marked success in treatment of hematologic malignancies, are an emergent therapeutic for patients with glioblastoma (GBM). GBM CAR-T trials have focused on targeting well-characterized antigens in the pathogenesis of GBM.
Thilan, Tudor +2 more
openaire +2 more sources
Chimeric antigen receptor T (CAR-T) cells, an immunotherapy that demonstrates marked success in treatment of hematologic malignancies, are an emergent therapeutic for patients with glioblastoma (GBM). GBM CAR-T trials have focused on targeting well-characterized antigens in the pathogenesis of GBM.
Thilan, Tudor +2 more
openaire +2 more sources
The Journal of Dermatology, 1980
AbstractCutaneous T cell lymphoma (CTCL) is a generic classification of clonally‐derived malignancies of phenotypic helper/inducer T cells with a propensity to infiltrate the skin, migrate into the epidermis, localize in T cell zones of lymphoid structures and spare the bone marrow.
openaire +3 more sources
AbstractCutaneous T cell lymphoma (CTCL) is a generic classification of clonally‐derived malignancies of phenotypic helper/inducer T cells with a propensity to infiltrate the skin, migrate into the epidermis, localize in T cell zones of lymphoid structures and spare the bone marrow.
openaire +3 more sources